Healthcare Industry News: MicroThermX
News Release - February 3, 2011
BSD Medical Announces Successful MicroThermX(R) Ablation Cancer Treatments at Four Prestigious Hospitals in ItalySALT LAKE CITY--(Healthcare Sales & Marketing Network)-- BSD Medical Corporation (NASDAQ:BSDM ) (Company or BSD) today announced the successful treatment of four cancer patients at prestigious hospitals in Italy using BSD's innovative new MicroThermX® Microwave Ablation System. The treatments were conducted within a four-day period and were attended by numerous key Italian physicians. Med-Italia Biomedica (Med-Italia), one of the largest interventional radiology/oncology distributors in Italy, purchased the MicroThermX® system and coordinated the delivery of the treatments.
The four participating hospitals included some of Italy's leading hospitals: Ospedaliera Spedali Civili in Brescia, one of the largest hospitals in Northern Italy; Istituto Clinico Humanitas in Rozzano, a teaching center for the University of Milan’s International Medical School; Instituto Europeo Di Oncologia in Milano, a leading cancer treatment hospital and home to Umberto Veronesi, MD, one of Italy’s most respected cancer surgeons; and Ospedale di San Giovanni Battista in Torino, the oldest hospital in Torino and the largest hospital in Piedmont.
BSD personnel monitored the procedures and provided training to Med-Italia's Director, Sales Manager, Engineering Manager, and 24 of its sales representatives. All 24 sales representatives are now actively selling the MicroThermX® systems throughout Italy. Med-Italia (http://www.meditalia.net) is a major distributor and manufacturer of products designed for the interventional radiology and oncology market in Italy. Med-Italia is an exclusive distributor in Italy for a number of large medical companies, selling strategically adjacent products to the same clinicians and market that will be targeted for the MicroThermX® System.
About the MicroThermX® Microwave Ablation System (MTX-180)
The MTX-180 is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The innovative design of the MTX-180 is the first of its kind that allows delivery of higher power levels using a single generator. The MTX-180 utilizes innovative synchronous phased array technology that was developed and patented by BSD to provide larger and more uniform zones of ablation during a single procedure. The MTX-180 introduces into the Company’s product line an innovative, high-end disposable that is used in each ablation treatment, and will provide a significant ongoing revenue stream. The soft tissue ablation world market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MTX-180 for ablation of soft tissue. BSD has also received CE Marking for the MTX-180 System.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market and well established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.
Source: BSD Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.